Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/6/2025

Management of Anemia in Adults

Initial Assessment and Diagnosis

  • Iron deficiency anemia occurs in 2-5% of adult men and post-menopausal women in the developed world, requiring thorough investigation 1
  • A PCV of 20 corresponds to a severely low hemoglobin level, warranting urgent evaluation and treatment, with the American Gastroenterological Association recommending prompt diagnostic workup 2
  • Serum ferritin is the most powerful test for diagnosing iron deficiency, with levels <12 μg/dL being diagnostic, according to the European Society for Medical Oncology 3, 1
  • Additional testing should include complete blood count with red cell indices, reticulocyte count, iron studies, vitamin B12 and folate levels, as recommended by the American Society of Anesthesiologists 4

Gastrointestinal Evaluation

  • In post-menopausal women, gastrointestinal blood loss is the most common cause of IDA, necessitating thorough GI investigation, with the American College of Gastroenterology recommending upper GI endoscopy and small bowel biopsies 1, 5
  • Upper GI endoscopy with small bowel biopsies should be performed, as 2-3% of patients with IDA have celiac disease, according to the North American Society for the Study of Celiac Disease 3
  • Lower GI tract examination is essential, as dual pathology occurs in 10-15% of patients, with the American Society for Gastrointestinal Endoscopy recommending colonoscopy or barium enema 3, 6
  • Common GI causes include colonic cancer/polyps, gastric cancer, angiodysplasia, peptic ulcer disease, and inflammatory bowel disease, with the European Society of Gastrointestinal Endoscopy recommending thorough evaluation 6, 5

Treatment Approach

Iron Supplementation

  • All patients should receive iron supplementation to correct anemia and replenish body stores, with the World Health Organization recommending oral iron therapy 7, 8
  • Oral iron therapy should be initiated with ferrous sulfate 200 mg three times daily, or equivalent ferrous gluconate or ferrous fumarate, as recommended by the National Institute of Diabetes and Digestive and Kidney Diseases 8
  • Iron supplementation should be continued for three months after correction of anemia to replenish iron stores, with the American Society of Hematology recommending ongoing supplementation 7
  • The hemoglobin concentration should rise by approximately 2 g/dL after 3-4 weeks of oral iron therapy, according to the European Hematology Association 8

Parenteral Iron Therapy

  • Intravenous iron should be considered when there is intolerance to at least two oral preparations or non-compliance, with the American College of Physicians recommending parenteral iron therapy 8
  • In patients with inflammatory bowel disease and moderate to severe IDA, intravenous iron is indicated for those intolerant to oral iron, according to the Crohn's and Colitis Foundation 2

Blood Transfusion

  • Blood transfusion should be considered when hemoglobin decreases to less than 7.5 g/dL and/or there are clinical symptoms and/or no response to other therapeutic measures, with the American Association of Blood Banks recommending transfusion 9
  • Transfusion of 2-3 units of packed cells is recommended to address an acute episode while avoiding complications from volume overload, according to the European Society of Anaesthesiology 9
  • Do not transfuse more than the minimum number of RBC units necessary to relieve symptoms or return the patient to a safe hemoglobin range, with the American Society of Clinical Oncology recommending judicious transfusion 10

Follow-up and Monitoring

  • Once normal, the hemoglobin concentration and red cell indices should be monitored at three-month intervals for one year and then after a further year, with the British Society of Gastroenterology recommending regular monitoring 7
  • Additional oral iron should be given if the hemoglobin or MCV falls below normal, according to the European Society for Medical Oncology 7
  • Further investigation is only necessary if the hemoglobin and MCV cannot be maintained with iron supplementation, with the American Gastroenterological Association recommending targeted evaluation 7

Special Considerations

  • The appropriateness of investigating patients with severe co-morbidity or advanced age should be carefully considered, especially if the results would not influence management, with the American College of Physicians recommending individualized assessment 7